NCT03287635View on ClinicalTrials.gov

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

March 4, 2020

Conditions
Dry Eye Disease
Interventions
DRUG

Corticotropin 80Unit/Ml Repository Injection

H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.

Trial Locations (1)

37203

Toyos Clinic, Nashville

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Toyos Clinic

OTHER

NCT03287635 - Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter